Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Almada – page 21

673 clinical trials in Almada, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Almada at a glance
673
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

673 trials in Almada

Open in trial search

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, pimecrolimus and tacrolimus in adults with severe chronic pruritus of unknown origin (CPUO): a randomized, placebo‑controlled trial

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Bronchiectasis

Not yet recruiting

Efficacy and safety of galvokimig in adults with non‑cystic fibrosis bronchiectasis: a randomized, double‑blind, placebo‑controlled phase 2 trial

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.

Conjunctivitis allergic+1

Not yet recruiting

Efficacy and safety of Depigoid Olea 1000 DPP/ml compared with placebo in patients with moderate to severe allergic rhinoconjunctivitis due to olive pollen

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:LETI Pharma S.L.U.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Interstitial lung disease+1

Not yet recruiting

A Phase 2 Study Evaluating the Safety and Efficacy of Oral NS-863 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Almada

What the registry says about research in the country

01 Respiratory and Pulmonary Research

Clinical trials focusing on pulmonary arterial hypertension and chronic obstructive pulmonary disease, evaluating novel treatments including ralinepag and itepekimab for long-term management of these conditions.

  • COPD Treatment Development
  • Pulmonary Hypertension Therapy
  • Long-term Safety Studies
02 Autoimmune and Inflammatory Conditions

Research investigating treatments for systemic lupus erythematosus, rheumatoid arthritis, and other inflammatory conditions, with studies on medications like upadacitinib and remibrutinib.

  • Lupus Management
  • Arthritis Treatments
  • Inflammatory Disease Therapies
03 Neurological Disorders

Studies examining treatments for multiple sclerosis, migraine prevention, and neurological conditions, testing medications such as ocrelizumab and atogepant.

  • MS Treatment Evaluation
  • Migraine Prevention
  • Neurological Disease Management
04 Cardiovascular Research

Investigations into hypertrophic cardiomyopathy and stroke prevention, studying treatments like mavacamten and asundexian for improved cardiac outcomes.

  • Heart Disease Management
  • Stroke Prevention
  • Cardiac Structure Studies
05 Oncology Research

Advanced studies in lung cancer, colorectal cancer, and head and neck cancers, evaluating novel immunotherapy combinations and targeted treatments.

  • Cancer Immunotherapy
  • Targeted Cancer Treatments
  • Metastatic Disease Management
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.